TRAQinform Assessment of Immunotherapy Response

Melanoma Clinical Trial

— AIQ TRAQinform  

Official title:

Comprehensive Assessment of Cancer Immunotherapy Response; Investigating the Intent to Change Treatment Decisions Based Upon TRAQinform Immuno Technology

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05819255
• Other study ID #: AIQ 22-583
• Secondary ID: 2R44CA257253
• Status: Recruiting
• Start date: June 23, 2023
• Est. completion date: August 2024

Study information

• Verified date: July 2023
• Source: AIQ Solutions
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study. Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent immunotherapy will be enrolled. Subjects will receive SOC immunotherapy monitored for treatment response with FDG PET/CT's at baseline (SOC), after 3-4 weeks of treatment (non-SOC) and 12 at weeks of treatment (SOC).

Description:

This prospective, non-interventional clinical study will enroll patients with metastatic melanoma, who have been selected by their oncologist to receive standard of care (SOC) dual-agent immunotherapy and monitored for treatment response using SOC FDG PET/CTs.

The primary objective of this clinical study is to investigate intent to change treatment decisions after the addition of treatment response information from the TRAQinform Immuno technology. For each subject, FDG PET/CT #1, #2 and #3 will be transmitted to AIQ Solutions (Madison, WI) for treatment response analysis using TRAQinform Immuno, a software technology that identifies, matches and quantifies metastatic cancer regions of interest. A TRAQinform Immuno report will be returned to the oncology/nuclear medicine paired investigator teams, after the first clinical decision point following FDG PET/CT #1 and #2 and again after the second clinical decision point following FDG PET/CT #3. The investigator team at each site will complete an "intent to change" questionnaire for each subject at Data Collection Point #1 and at Data Collection Point #2. The clinical study will evaluate the Data Collection Point questionnaires to help understand the clinical impact of the addition of TRAQinform Immuno analysis into the clinical workflow.

To address the status quo bias of the investigator teams, the TRAQinform Immuno reports for subjects enrolled at each site, including the additional limited data that is necessary to make a treatment decision, will be shared between teams. The first investigator team, without knowledge of the treatment decision made by the second investigator team, will independently answer the Data Collection Point #3 questionnaire and vice versa.

An exploratory objective of this clinical trial is to investigate if treatment effectiveness and adverse events could be detected on FDG PET/CT images at 3-4 weeks of the combination immunotherapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 32
• Est. completion date: August 2024
• Est. primary completion date: May 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of metastatic melanoma and is planned to start or has received one cycle of treatment with standard of care, dual-agent immunotherapy.

• Previous adjuvant anti-PD-I monotherapy is allowed. Patients must be greater than 6 months from the last treatment.

• Previous adjuvant BRAF/MEK therapy is allowed.

• Ability to tolerate 3 FDG PET/CT procedures. One at baseline, prior to the start of the combination immuno therapy, after 3 - 4 weeks of the combination immunotherapy treatment, and at 12 weeks of the combination treatment.

• Estimated life expectancy of greater than 12 months at screening.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at screening.

• Deemed suitable for starting standard of care combination immunotherapy for metastatic melanoma.

• Willing and able to provide informed consent for FDG PET/CT imaging.

Exclusion Criteria:

• Any concurrent disease, infection, or comorbid condition that interferes with the ability of the patient to participate in the trial; places the patient at undue risk; or complicates the interpretation of the data, in the opinion of the investigator.

• A second malignancy

• Pregnancy or women who are breast feeding

Related Conditions & MeSH terms

• Melanoma

Intervention

Other:
• Non-Interventional
This prospective, non-interventional clinical study will enroll patients with metastatic melanoma, who have been selected by their oncologist to receive standard of care dual-agent immunotherapy and monitored for treatment response using SOC FDG PET/CTs. The primary objective of this clinical study is to investigate intent to change treatment decisions after the addition of treatment response information from the TRAQinform Immuno technology.

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	University of Wisconsin Carbone Cancer Center	Madison	Wisconsin

Sponsors (4)

Lead Sponsor	Collaborator
AIQ Solutions	Massachusetts General Hospital, National Cancer Institute (NCI), University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To Investigate Intent to Change Treatment Decisions.	Treatment response will be analyzed using TRAQinform Immuno Technology which is a software technology that identifies, matches, and quantifies metastatic cancer regions of interest. The clinical study will evaluate investigator questionaries to help understand the clinical impact of the addition of the TRAQinform Immuno analysis into the clinical work flow.	12 weeks
Secondary	Adverse Events and Treatment Efficacy Prediction	To investigate if treatment effectiveness and adverse events can be detected on week 3-4 FDG PET/CT. An additional FDG PET/CT will be obtained on all subjects between weeks three and four to evaluate if TRAQinform Immuno can predict adverse events and treatment effectiveness.	4 weeks